FDA updates watch list by adding 3 drugs

02/13/2013 | Medscape (free registration)

The FDA added GlaxoSmithKline's leukemia drug Arzerra, or ofatumumab; UCB's epilepsy, liver and kidney drug Vimpat, or lacosamide; and Acorda Therapeutics' multiple sclerosis, kidney and liver drug Ampyra, or dalfampridine, to its list of products to monitor due to new safety information or possible signs of serious risks. The FDA received reports of potential adverse events involving the treatments in last year's third quarter. A sunscreen was also added to the list.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA